SER

Serina Therapeutics, Inc. develops advanced drug delivery systems utilizing its proprietary POZ Platform™, which enhances the performance of established small molecule therapeutics. The company focuses on optimizing pharmacokinetics through a process called POZylation, which improves drug efficacy, reduces dosing frequency, and minimizes side effects. Its lead product candidate, SER-252 (POZ-apomorphine), is designed for the treatment of advanced Parkinson's disease, offering a more convenient administration method compared to traditional infusion therapies. Serina operates primarily in the pharmaceutical sector, targeting patients with chronic conditions and leveraging regulatory pathways to expedite drug development.